Total Payments
$1,880
2024 Payments
$675.46
Companies
27
Transactions
119
Medicare Patients
2,588
Medicare Billing
$628,859
Payment Breakdown by Category
Food & Beverage$1,284 (68.3%)
Education$596.34 (31.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,284 | 85 | 68.3% |
| Education | $596.34 | 34 | 31.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $544.38 | 46 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $305.31 | 19 | $0 (2024) |
| ABBVIE INC. | $199.73 | 11 | $0 (2024) |
| BeiGene USA, Inc. | $125.37 | 7 | $0 (2024) |
| Seagen Inc. | $99.00 | 1 | $0 (2020) |
| Astellas Pharma US Inc | $95.00 | 1 | $0 (2020) |
| Celgene Corporation | $81.93 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $44.60 | 3 | $0 (2021) |
| Genentech USA, Inc. | $43.27 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $41.47 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $675.46 | 41 | PFIZER INC. ($190.95) |
| 2023 | $366.76 | 26 | PFIZER INC. ($194.82) |
| 2022 | $185.74 | 12 | PFIZER INC. ($51.74) |
| 2021 | $56.71 | 4 | Celgene Corporation ($17.78) |
| 2020 | $194.00 | 2 | Seagen Inc. ($99.00) |
| 2019 | $32.98 | 3 | Genentech USA, Inc. ($17.70) |
| 2018 | $234.44 | 21 | PFIZER INC. ($106.87) |
| 2017 | $133.89 | 10 | Novartis Pharmaceuticals Corporation ($35.47) |
All Payment Transactions
119 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $14.95 | General |
| 12/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Oncology | ||||||
| 12/11/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Oncology | ||||||
| 11/01/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Oncology | ||||||
| 10/22/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.77 | General |
| Category: Hematology | ||||||
| 08/21/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.88 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $7.98 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $23.76 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Oncology | ||||||
| 07/01/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 513 | 1,090 | $230,062 | $83,597 |
| 2022 | 9 | 633 | 1,375 | $287,468 | $126,906 |
| 2021 | 10 | 743 | 1,998 | $404,414 | $222,956 |
| 2020 | 9 | 699 | 1,936 | $379,714 | $195,401 |
Total Patients
2,588
Total Services
6,399
Medicare Billing
$628,859
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 715 | $149,435 | $54,442 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 140 | 178 | $25,276 | $9,545 | 37.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $17,435 | $5,667 | 32.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 57 | $13,167 | $5,233 | 39.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 37 | $10,397 | $4,108 | 39.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 23 | $10,327 | $3,078 | 29.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 25 | $4,025 | $1,525 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 271 | 873 | $182,457 | $75,524 | 41.4% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 36 | 105 | $16,800 | $16,773 | 99.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 134 | 162 | $23,004 | $10,385 | 45.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 45 | 53 | $14,893 | $7,057 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $17,435 | $6,420 | 36.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 38 | 42 | $18,858 | $6,161 | 32.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 27 | $6,237 | $2,007 | 32.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 37 | $5,957 | $1,966 | 33.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 21 | $1,827 | $612.78 | 33.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 296 | 993 | $207,537 | $91,873 | 44.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 96 | 559 | $89,440 | $89,563 | 100.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 83 | 83 | $26,311 | $10,152 | 38.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 53 | 64 | $17,984 | $8,412 | 46.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 43 | $19,307 | $6,534 | 33.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 96 | 108 | $15,336 | $6,364 | 41.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 53 | $12,243 | $4,088 | 33.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 53 | $8,533 | $2,935 | 34.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $5,200 | $2,210 | 42.5% |
About Dr. Jihad Khattab, MD
Dr. Jihad Khattab, MD is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730126111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jihad Khattab, MD has received a total of $1,880 in payments from pharmaceutical and medical device companies, with $675.46 received in 2024. These payments were reported across 119 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($1,284).
As a Medicare-enrolled provider, Khattab has provided services to 2,588 Medicare beneficiaries, totaling 6,399 services with total Medicare billing of $628,859. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/02/2006
- Last Updated 10/08/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1730126111
Products in Payments
- IBRANCE (Drug) $295.92
- BRUKINSA (Drug) $125.37
- VENCLEXTA (Drug) $125.14
- INLYTA (Drug) $116.08
- PLUVICTO (Drug) $98.03
- PROMACTA (Drug) $72.29
- IMBRUVICA (Drug) $56.36
- ELIQUIS (Drug) $51.92
- XTANDI (Drug) $51.12
- REBLOZYL (Biological) $49.20
- IMFINZI (Drug) $41.47
- NINLARO (Drug) $35.51
- KISQALI (Drug) $35.49
- MEKINIST (Drug) $34.83
- Onivyde (Drug) $32.46
- VENCLEXTA (Biological) $30.23
- SCEMBLIX (Drug) $29.31
- BELEODAQ (Drug) $25.90
- ORGOVYX (Drug) $23.93
- JADENU (Drug) $23.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Mark Olsen, M.d, M.D
Hematology & Oncology — Payments: $4,652
Hematology & Oncology $4,652
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488